Events Generic Medicine Packaging 
Express Pharma
MARCH 12, 2025
The Indian Pharmaceutical Alliance (IPA) questions the reliance on the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) in the Ohio State University report titled, Are All Generic Drugs Created Equal? An Empirical Analysis of Generic Drug Manufacturing Location and Serious Drug Adverse Events.
PharmaState Academy
JANUARY 29, 2024
Discussions also covered the hierarchy in international marketing, expected packages, responsibilities, and territories of medical representatives and country managers. He highlighted potential opportunities due to the low cost of skilled labor, expanding market size, and increasing global demand for generic drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 30, 2023
A spokesperson for the agency stated, “Shortages can have multiple causes, including manufacturing problems causing delays or interruption in the production, shortages of raw materials, increased demand of medicines, distribution problems, labour disruptions, and natural disasters.”
European Pharmaceutical Review
FEBRUARY 2, 2023
This reliance on sourcing API from other nations puts Europe’s entire manufacturing cycle at risk, especially in the event of global crises and geopolitical tensions. This is likely to make some essential medicines and APIs economically unsustainable to manufacture.
Quality Matters
APRIL 26, 2023
FDA are co-hosting the APEC Medical Product Supply Chain Dialogue as a signature event of the U.S. In my keynote remarks, I highlighted the following elements of a strong medicines supply chain. in a platform that assesses the vulnerability of specific medicines to supply chain disruptions. To advance this goal, USP and the U.S.
pharmaphorum
MAY 26, 2022
Factors such as ethnicity, gender, sexual orientation and age can contribute to interindividual differences in treatment responses and risks of adverse events. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines. About the authors.
Expert insights. Personalized for you.
66 
Let's personalize your content